Neogen Corporation

NEOG ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-7.9M $-1.09B $-9.4M $-22.9M $48.3M $60.9M $59.5M $60.2M
Depreciation & Amortization $116.3M $119.5M $116.7M $88.4M $23.7M $21.0M $18.4M $17.6M
Depreciation $24.4M $25.6M $21.8M $17.3M $14.1M $13.3M $11.9M $11.3M
Amortization $91.8M $93.9M $94.9M $71.1M $9.6M $7.8M $6.5M $6.3M
Stock-Based Compensation $13.4M $17.3M $13.8M $10.2M $7.2M $6.4M $6.5M $5.5M
Net Cash from Operating Activities $83.2M $58.2M $35.3M $41.0M $68.0M $81.1M $85.9M $63.8M
Investing Activities
Capital Expenditures $51.3M $104.6M $111.4M $65.8M $24.4M $26.7M $24.1M $14.7M
Business Acquisitions $0 $0 $-11.7M $38.7M $50.8M $13.2M $6.4M
Net Cash from Investing Activities $70.5M $-99.2M $-29.3M $201.0M $-97.2M $-105.6M $-88.8M $-119.1M
Financing Activities
Dividends Paid
Stock Repurchases $3.1M
Net Cash from Financing Activities $-99.4M $-1.6M $1.9M $-118.1M $6.8M $33.5M $29.4M $13.9M
Net Change in Cash $56.5M $-41.6M $7.4M $118.8M $-31.1M $9.3M $24.6M $-41.4M
Free Cash Flow $31.9M $-46.4M $-76.1M $-24.7M $43.6M $54.4M $61.8M $49.2M
← Newer Page 1 of 3 Older →